US 11065285
Biomarkers and combination therapies using oncolytic virus and immunomodulation
granted A61KA61K2039/505A61K31/454
Quick answer
US patent 11065285 (Biomarkers and combination therapies using oncolytic virus and immunomodulation) held by The Board of Regents of the University of Texas System expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K31/454, A61K35/761, A61K38/2013